- Home
- BBU vs KNSA Comparison
BBU vs KNSA Comparison
Compare BBU & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBU | KNSA |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | Bermuda | United Kingdom |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BBU | KNSA |
|---|---|---|
| Price | $31.46 | $53.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $39.40 | ★ $60.86 |
| AVG Volume (30 Days) | 149.9K | ★ 752.4K |
| Earning Date | 05-01-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | N/A | $37.48 |
| Revenue Next Year | N/A | $17.87 |
| P/E Ratio | ★ N/A | $198.74 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $23.31 | $25.71 |
| 52 Week High | $37.75 | $59.87 |
Technical Indicators
Market Signals| Indicator | BBU | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 51.33 |
| Support Level | $29.90 | $40.67 |
| Resistance Level | $36.93 | $59.87 |
| Average True Range (ATR) | 1.38 | 2.05 |
| MACD | 0.23 | -0.43 |
| Stochastic Oscillator | 46.92 | 12.98 |
Price Performance
Historical ComparisonAbout BBU Brookfield Business Partners L.P. Limited Partnership Units
Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.